In conclusion, our study identified EZH2 gain as a biomarker for selecting patients with BRAF V600E-mutated melanoma who may benefit from combination therapy with BRAF and EZH2 inhibitors, thus providing insights into a promising novel therapeutic strategy for the treatment of melanoma. This evidence concerns the gene EZH2 and melanoma.